Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Warfarin is very effective in preventing recurrent venous thromboembolism but is also associated with a substantial risk of bleeding. After three months of conventional warfarin therapy, a lower dose of anticoagulant medication may result in less bleeding and still prevent recurrent venous thromboembolism. METHODS: We conducted a randomized, double-blind study, in which 738 patients who had completed three or more months of warfarin therapy for unprovoked venous thromboembolism were randomly assigned to continue warfarin therapy with a target international normalized ratio (INR) of 2.0 to 3.0 (conventional intensity) or a target INR of 1.5 to 1.9 (low intensity). Patients were followed for an average of 2.4 years. RESULTS: Of 369 patients assigned to low-intensity therapy, 16 had recurrent venous thromboembolism (1.9 per 100 person-years), as compared with 6 of 369 assigned to conventional-intensity therapy (0.7 per 100 person-years; hazard ratio, 2.8; 95 percent confidence interval, 1.1 to 7.0). A major bleeding episode occurred in nine patients assigned to low-intensity therapy (1.1 events per 100 person-years) and eight patients assigned to conventional-intensity therapy (0.9 event per 100 person-years; hazard ratio, 1.2; 95 percent confidence interval, 0.4 to 3.0). There was no significant difference in the frequency of overall bleeding between the two groups (hazard ratio, 1.3; 95 percent confidence interval, 0.8 to 2.1). CONCLUSIONS: Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long-term prevention of recurrent venous thromboembolism. The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
In the citing paper
“However, it should be noted that patients considered to have a ' high risk of bleeding ' were excluded from the randomized trial described in the analysis above. 316”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [316]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“[7] Hazard ratios associated with low-intensity therapy as compared with conventional-intensity therapy (with 95 percent confidence intervals) and log-rank tests were used to compare the treatment groups.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079 · cited 1×
“Assays for factor V Leiden [4] and the G20210A mutation in the prothrombin gene [5] were performed in a central laboratory by technologists who were unaware of the patient's treatment-group assignment and clinical course.”
MethodOral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804 · cited 1×
“0 per 100 patient-years among those assigned to low-intensity therapy, [6] an average of 2.”
BackgroundSelf-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072 · cited 5×
“As in other studies, [2,10] factor V Leiden and prothrombin-gene mutations were not associated with a higher risk of recurrent thromboembolism, although all patients in our study were treated with anticoagulant therapy.”
BackgroundResultInfluentialSelf-citationNatural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 2×
“Collectively, the results of our study and the three other trials that have evaluated extended treatment of patients who have had unprovoked venous thromboembolism [2,3,9] suggest that low-intensity anticoagulant therapy reduces the risk of recurrent thrombosis by about 75 percent, whereas conventional-intensity thera…”
BackgroundResultBeyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Research works printed but not linked: 3
- Kearon C, 2003, Circulation, 107, I
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
Cited by
Items 201–300 of 748
Current strategies to minimize the bleeding risk of warfarin
Snipelisky, D., & Kusumoto (2013) · Journal of Blood Medicine · doi:10.2147/jbm.s41404 · Cited by 44
Cosmi, B., Legnani, C., Tosetto, A., Pengo, V., Ghirarduzzi, A., Testa, S., Prisco, D., Poli, D., Tripodi, A., & Palareti, G. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03955.x · Cited by 43
Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation
Vazquez, S. R., Johnson, S. A., & Rondina, M. T. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2009.11.031 · Cited by 39
Venous thromboembolic prophylaxis for hip fractures
Marsland, D., Mears, S. C., & Kates, S. L. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1403-2 · Cited by 40
Newman, D. H., & Zhitomirsky, I. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2005.12.010 · Cited by 40
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
Cavallari, L. H., Jeong, & Bress, A. P. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s15497 · Cited by 48
Anticoagulation in the Elderly
Robert‐Ebadi, H., & Righini, M. (2010) · Pharmaceuticals · doi:10.3390/ph3123543 · Cited by 43
McBane, R. D., Felty, C. L., Hartgers, M. L., Chaudhry, R., Beyer, L. K., & Santrach, P. J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.2.181 · Cited by 39
Rusdiana, T., Araki, T., Nakamura, T., Subarnas, A., & Yamamoto, K. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1356-9 · Cited by 38
“showed that low-dose WF did not reduce the risk of bleeding compared to conventional-intensity WF therapy [2], while the risk of bleeding increased when WF was combined with other cardiovascular drugs, such as aspirin [18].”
BackgroundSeiler, E., Limacher, A., Mean, M., Beer, H.-J., Osterwalder, J., Frauchiger, B., Righini, M., Aschwanden, M., Matter, C. M., Banyai, M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th-17-03-0162 · Cited by 43
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis.
Wang, K.-L., Chu, P. H., Lee, C., Pai, P. Y., Lin, P.-Y., Shyu, K. G., Chang, W., Chiu, K., Huang, C.-L., Lee, C. Y., et al. (2016) · Europe PMC (PubMed Central) · doi:10.6515/acs20151228a · Cited by 49
Pirmohamed, M., & Ferner, R. E. (2003) · BMJ · doi:10.1136/bmj.327.7425.1179 · Cited by 38
“We all want our treatments to work, and none of us wishes treatment to cause harm. Monitoring drug treatment is one way of seeing that a treatment works, while protecting the patient from adverse drug effects. For many patients and many treatments clinical evaluation is sufficient. An example is measuring the blood pr…”
BackgroundRahimi, Z., Vaisi‐Raygani, A., Mozafari, H., Kharrazi, H., Rezaei, M., & Nagel, R. L. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0052-6 · Cited by 37
Burgess, S., Crown, N., Louzada, M., Dresser, G. K., Kim, R. B., & Lazo‐Langner, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12352 · Cited by 39
Cios, D. A., Baker, W. L., Sander, S. D., Phung, O. J., & Coleman, C. I. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080507 · Cited by 37
Wan, T., Rodger, M. A., Zeng, W., Robin, P., Righini, M., Kovacs, M. J., Tan, M., Carrier, M., Kahn, S. R., Wells, P. S., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.11.020 · Cited by 38
Self-citationFirst-generation agents: aspirin, heparin and coumarins
Mueller, R. L. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.03.003 · Cited by 45
Venous Thromboembolism in Children
Goldenberg, N. A., & Bernard, T. J. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2008.01.003 · Cited by 37
“Further study to optimize the intensity and duration of therapy or secondary prophylaxis for VTE in children who have APA syndrome urgently is needed, however, especially given the recent evidence in adult VTE that secondary prophylaxis with low-dose warfarin not only may offer little risk reduction beyond no anticoag…”
BackgroundFeng, L., Yang, L., Li, J., & Yu, B. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0498 · Cited by 36
Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation
O’Shea, S. I., Arcasoy, M. O., Samsa, G. P., Cummings, S. E., Thames, E. H., Surwit, R. S., & Ortel, T. L. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0068-y · Cited by 35
“In addition recent evidence suggests long-term warfarin is effective in preventing recurrence of venous thrombosis [2, 3].”
BackgroundLawrence, M. J., Sabra, A., Mills, G. M., Pillai, S., Abdullah, W., Hawkins, K. M., Morris, R. H., Davidson, S. J., D׳Silva, L., Curtis, D. J., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13173 · Cited by 35
Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism
WHITE, R. H., Murin, S., Wun, T., & Danielsen, B. H. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03798.x · Cited by 37
A review of the oral direct thrombin inhibitor ximelagatran
Mohapatra, R., Tran, M. T., Gore, J. M., & Spencer, F. A. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.012 · Cited by 35
Venous thromboembolism: diagnosis and management of pulmonary embolism
Lee, C. H., Hankey, G. J., Ho, W. K., & Eikelboom, J. W. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06816.x · Cited by 35
Mai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation
Barnes, G. D., Kanthi, Y. M., & Froehlich, J. B. (2015) · Vascular Medicine · doi:10.1177/1358863x14566429 · Cited by 40
The management of thromboembolic disease in patients with central nervous system malignancies
Knovich, M. A., & Lesser, G. J. (2004) · Current Treatment Options in Oncology · doi:10.1007/s11864-004-0039-x · Cited by 34
Garcia, D. A., Khamashta, M. A., & Crowther, M. A. (2007) · Blood · doi:10.1182/blood-2006-10-041814 · Cited by 34
Self-citationManagement of Venous Thromboembolism in the Elderly
Spyropoulos, A. C., & Merli, G. J. (2006) · Drugs & Aging · doi:10.2165/00002512-200623080-00003 · Cited by 35
Cosmi, B., Legnani, C., Tosetto, A., Pengo, V., Ghirarduzzi, A., Alatri, A., Prisco, D., Poli, D., Tripodi, A., & Palareti, G. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0315-5 · Cited by 33
A Rational Approach to the Diagnosis and Management of Thrombocytopenia in the Hospitalized Patient
Arnold, D. M., & Lim, W. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2011.08.002 · Cited by 33
Predictors of recurrent venous thromboembolism and bleeding on anticoagulation
Menapace, L. A., McCrae, K. R., & Khorana, A. A. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30106-2 · Cited by 33
Wille, K., Sadjadian, P., Becker, T. M., Kolatzki, V., Horstmann, A., Fuchs, C., & Grießhammer, M. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3483-6 · Cited by 34
Simpson, E. L., Stevenson, M., Rawdin, A., & Papaioannou, D. E. (2009) · Health Technology Assessment · doi:10.3310/hta13020 · Cited by 38
Improving Anticoagulation Therapy Using Point-of-Care Testing and a Standardized Protocol
Franke, C. A., Dickerson, L. M., & Carek, P. J. (2008) · The Annals of Family Medicine · doi:10.1370/afm.739 · Cited by 32
Antiphospholipid antibiodies: a critical review of the literature
Lim, W., & Crowther, M. A. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3282a4a65f · Cited by 33
Self-citationTreatment of antiphospholipid syndrome
Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Menegatti, E., Roccatello, D., & Sciascia, S. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108597 · Cited by 35
Duration of Anticoagulation Therapy for Venous Thromboembolism
Bounameaux, H., & Perrier, A. (2008) · Hematology · doi:10.1182/asheducation-2008.1.252 · Cited by 32
Optimal Duration of Anticoagulation After Venous Thromboembolism
Goldhaber, S. Z., & Piazza, G. (2011) · Circulation · doi:10.1161/circulationaha.110.970822 · Cited by 33
Thrombophilia: Clinical and Laboratory Assessment and Management
Heit, J. A. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10014-8 · Cited by 35
Helft, G., Gilard, M., Feuvre, C. L., & Zaman, A. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0712 · Cited by 34
“Although the benefit of treatment with vitamin K antagonists is partly offset by the risk of major bleeding”
BackgroundRondina, M. T., Wanner, N., Pendleton, R. C., Kraiss, L. W., Vinik, R., Zimmerman, G. A., Heilbrun, M. E., Hoffman, J. M., & Morton, K. A. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.025 · Cited by 30
Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy
Lu, D.-Y., Chen, X. L., & Ding, J. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.06.045 · Cited by 30
Pathways to poor anticoagulation control
Razouki, Z. A., Ozonoff, A., Zhao, S., & Rose, A. J. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12530 · Cited by 30
Wilke, R. A., Berg, R. L., Vidaillet, H. J., Jr., Caldwell, M. D., Burmester, J. K., & Hillman, M. A. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.4.207 · Cited by 32
Pulmonary embolism in hospital practice
Robinson, G. V. (2006) · BMJ · doi:10.1136/bmj.332.7534.156 · Cited by 30
Oral anticoagulation strategies after a first idiopathic venous thromboembolic event
Aujesky, D., Smith, K. J., & Roberts, M. S. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.018 · Cited by 29
Nguyen, G. C., & Bernstein, C. N. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.220 · Cited by 29
Low-Intensity Adjusted-Dose Warfarin for the Prevention of Hemodialysis Catheter Failure
Wilkieson, T. J., Ingram, A. J., Crowther, M. A., Soroka, S., Nagai, R., Jindal, K. K., & Clase, C. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07240810 · Cited by 29
“In the general population, lower targets for INR have been found to be no safer than target INR 2 to 3 (21,22).”
BackgroundSelf-citationAnemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism
the RIETE Investigators, Kuperman, A. A., López-Reyes, R., Bosco, L., Lorenzo, A., Bascuñana, J., Farge, D., Alfonso, M., Lumbierres, M., Stemer, G., et al. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1610-9 · Cited by 30
Shorr, A. F., Jackson, W. L., Weiss, B. M., & Moores, L. K. (2007) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328099af58 · Cited by 30
Platelet count and outcome in patients with acute venous thromboembolism
Micco, P. D., Ruiz‐Giménez, N., Nieto, J. A., Aujesky, D., del Molino, F., Valle, R., Barrón, M., Maestre, A. M., Monréal, M., & the RIETE Investigators (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0352 · Cited by 29
Extended anticoagulation after venous thromboembolism: should it be done?
Fernandes, C. J. C. D. S., Calderaro, D., Piloto, B. M., Hoette, S., Jardim, C., & Souza, R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619878556 · Cited by 28
Frère, C., Font, C., Esposito, F. M., Crichi, B., Girard, P., & Janus, N. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06598-8 · Cited by 35
East, A. T., & Wakefield, T. W. (2010) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2010.05.006 · Cited by 28
Anticoagulation in Heart Failure: a Review.
Zeitler, E. P., & Eapen, Z. J. (2015) · Europe PMC (PubMed Central) · doi:10.4022/jafib.1250 · Cited by 35
El paciente anciano polimedicado: efectos sobre su salud y sobre el sistema sanitario
Blasco Patiño, F., Villares, P., & Ai, J. (2005) · Cited by 28
Wakefield, T. W., Caprini, J. A., & Comerota, A. J. (2008) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2008.08.002 · Cited by 32
Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes
Kearon, C. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02761.x · Cited by 30
Self-citationHow Fragile Are Clinical Trial Outcomes That Support the CHEST Clinical Practice Guidelines for VTE?
Edwards, E. A., Wayant, C., Besas, J., Chronister, J., & Vassar, M. B. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.01.031 · Cited by 28
“Complete FI/FQ data, presented alongside the number needed to treat for each outcome, are shown in Table 1.(10-27)”
MethodÖgren, M., & Schulman, S. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-05-0235 · Cited by 29
“In trials where patients were randomized to different intensities of anticoagulation (19, 64) and followed for at least two years, the risk of bleeding was much lower than in trials randomizing the patients at a maximum of three months after the index event (13, 14, 17, 18, 65) (Fig.”
BackgroundHuisman, M. V., van der Meer, F. J. M., van Rooden, C. J., & Prins, M. H. (2003) · New England Journal of Medicine · doi:10.1056/nejm200311273492216 · Cited by 27
Risk of thromboembolism after cerebral venous thrombosis
Maqueda, V., & Thijs, V. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01211.x · Cited by 27
“Two randomized trials in DVT patients suggest that long-term oral anticoagulation can reduce the risk of recurrent VTE by 75–90% [7,8].”
BackgroundRaggam, R. B., Hafner, F., Avian, A., Hackl, G., Cvirn, G., Brodmann, M., Gary, T., & Rief, P. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1607433 · Cited by 29
Kim, K., Yamashita, Y., Morimoto, T., Kitai, T., Yamane, T., Ehara, N., Kinoshita, M., Kaji, S., Amano, H., Takase, T., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692425 · Cited by 28
Piazza, G. (2015) · Vascular Medicine · doi:10.1177/1358863x14568706 · Cited by 30
Self-testing and self-management of oral anticoagulation therapy in children
Larsen, T. B., Hjortdal, V. E., & Christensen, T. D. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-04-0217 · Cited by 26
“5 % per year (6, 7), though highly dependent on selection of patients and definition of events.”
BackgroundPrandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
“0, may offer a suitable option for patients requiring longer periods of anticoagulation has long been debated [61,62].”
BackgroundHarenberg, J., Jörg, I., Vukojevic, Y., Mikus, G., & Weiß, C. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0463-0 · Cited by 26
Weitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 28
Self-citationNew Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
Miao, L., Shi, J., Yu, H., Song, L., Zhu, C., Shi, D., & Gao, J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029810 · Cited by 27
“19,20 Although there is no prospective study on the relationship between AF and VTE, these findings highlight groups of patients who may be at an increased risk of AF and VTE, and prevention strategies should be developed for these groups.”
BackgroundRose, A. J., Berlowitz, D. R., Miller, D. R., Hylek, E. M., Ozonoff, A., ZHAO, S., Reisman, J. I., & Ash, A. S. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04649.x · Cited by 25
Recent developments in the diagnosis and treatment of pulmonary embolism
van der Hulle, T., Dronkers, C. E. A., Klok, F. A., & Huisman, M. V. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12404 · Cited by 28
An Update on the Management of Chronic Thromboembolic Pulmonary Hypertension
Edward, J. A., & Mandras, S. A. (2016) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2016.11.001 · Cited by 25
Choumane, N. S., Malaeb, D. N., Malaeb, B., & Hallit, S. R. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2874-7 · Cited by 27
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020230 · Cited by 28
Self-citationFrei, A. N., Stalder, O., Limacher, A., Méan, M., Baumgartner, C., Rodondi, N., & Aujesky, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1726345 · Cited by 27
Nam, D., Sadhu, A., Hirsh, J. B., Keeney, J. A., Nunley, R. M., & Barrack, R. L. (2014) · The Journal of Arthroplasty · doi:10.1016/j.arth.2014.08.032 · Cited by 26
Prins, M. H., & Lensing, A. W. A. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-13 · Cited by 25
Quality use of generic medicines
Hassali, M. A., Stewart, K., & Kong, D. C. M. (2004) · Australian Prescriber · doi:10.18773/austprescr.2004.067 · Cited by 28
Robertson, L., Yeoh, S. E., & Ramli, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088.pub2 · Cited by 29
Margelidon-Cozzolino, V., Delavenne, X., Catella, J., Magalhaes, É. D., Bezzeghoud, S., Humbert, M. J. C., Montani, D., & Bertoletti, L. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.05.003 · Cited by 24
Sanada, Y., Kawano, Y., Mizuta, K., Egami, S., Hayashida, M., Wakiya, T., Fujiwara, T., Sakuma, Y., Hydo, M., Nakata, M., et al. (2010) · Liver Transplantation · doi:10.1002/lt.21995 · Cited by 24
Bleeding risks associated with vitamin K antagonists
Linkins, L. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.02.004 · Cited by 26
Reviews: Use of Warfarin in People with Low Glomerular Filtration Rate or on Dialysis
Holden, R. M., & Clase, C. M. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00632.x · Cited by 26
Lundström, T., Wåhlander, K., Clason, S. B., Schulman, S., Eriksson, H., & for the THRIVE III Investigators (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-02-0096 · Cited by 24
“Similar findings have been reported in trials of secondary prevention for VTE among patients receiving warfarin (10).”
MethodResultInfluentialRubenfire, M., Bayram, M., & Hector-Word, Z. (2007) · Critical Care Clinics · doi:10.1016/j.ccc.2007.07.006 · Cited by 24
Venous Thromboembolism Overview
Battinelli, E. M., Murphy, D. L., & Connors, J. M. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.010 · Cited by 23
Bleeding Risk Prediction Models in Atrial Fibrillation
Thomas, I. C., & Sorrentino, M. J. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0432-9 · Cited by 26
“Kearon et al. (2003) In the Extended Low-Intensity Anticoagulation for ThromboEmbolism (ELATE) trial, Kearon et al. prospectively compared low-intensity warfarin (target INR 1.5 to 1.9) therapy with conventional-intensity warfarin (INR 2.0 to 3.0) in 738 patients with unprovoked VTE.”
BackgroundInfluentialUpdate on extended treatment for venous thromboembolism
Peñaloza-Martínez, E., Rodríguez, P. D., Proietti, M., Fernández‐Llamazares, G. S., Mendo, C. L., Álvarez-Sala, J. L., Marra, A. M., & del Toro‐Cervera, J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1538564 · Cited by 26
Balancing risks and benefits of extended anticoagulant therapy for idiopathic venous thrombosis
Kearon, C. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03388.x · Cited by 24
Self-citationVenous Thromboembolic Events in the Rehabilitation Setting
Kelly, B. M., Yoder, B., Tang, C., & Wakefield, T. W. (2010) · PM&R · doi:10.1016/j.pmrj.2010.03.029 · Cited by 24
DVT: A New Era in Anticoagulant Therapy
Mackman, N., & Becker, R. C. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.203497 · Cited by 25
Ximelagatran: An orally active direct thrombin inhibitor
Gulseth, M. P. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp040534 · Cited by 23
Anticoagulation Management: A New Approach
Wurster, M., & Doran, T. (2006) · Disease Management · doi:10.1089/dis.2006.9.201 · Cited by 23
Ridker, P. M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00813.x · Cited by 23
Vitamin K and oral anticoagulation: thought for food
Bovill, E. G., Fung, M. K. Y., & Cushman, M. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.020 · Cited by 23
Inherited thrombophilia and life‐time risk of venous thromboembolism: is the burden reducible?
Stefano, V. D. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00863.x · Cited by 22
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment
Schindewolf, M., & Weitz, J. I. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400302 · Cited by 23
Self-citation
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., Turpie, A. G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, C., Kahn, S. R., Kassis, J., Rodger, M., Hambleton, J., & Gent, M.
- Affiliations
- McMaster University (CA)
- Western University (CA)
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of New Brunswick (CA)
- University of Toronto (CA)
- McGill University (CA)
- Université Laval (CA)
- Université de Montréal (CA)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-14
- Volume
- 349
- Issue
- 7
- Pages
- 631-639
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2009013630
- Cited by
- 751
- References
- 12
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 3 · 2023: 12 · 2022: 8 · 2021: 12 · 2020: 17 · 2019: 25 · 2018: 38 · 2017: 26 · 2016: 29 · 2015: 27 · 2014: 31 · 2013: 58 · 2012: 45
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, low-intensity anticoagulation, venous thromboembolism, recurrent venous thromboembolism, unprovoked venous thromboembolism, international normalized ratio, bleeding risk, anticoagulation intensity, long-term prophylaxis
- MeSH terms
- Age Factors, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk Factors, Warfarin, Treatment Outcome, International Normalized Ratio, Venous Thrombosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.